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Automated Sampling in Upstream Process
Development for Accelerated Access to Critical
Process Parameters (CPPs) and Critical Quality
Attributes (CQAs)
Srijana Chapagain, Rakesh Bobbala, Khin Myint, Allyson Caron
MilliporeSigma, Bedford, MA, USA

Introduction

Master
Controller

As biopharmaceutical manufacturers seek to efficiently develop
and deliver affordable biologics to patients, Process Analytical
Technologies (PAT) are being used to improve monitoring and
control of critical process parameters (CPPs) and assess their
impact on critical quality attributes (CQAs) of the product. PAT
tools are transitioning analytical monitoring from primarily
offline analysis to in-line or on-line measurement, accelerating
access to process information while enabling process control to
facilitate real-time release. One of these enabling PAT tools are
automated sampling systems, which can aseptically pull a
sample from a process stream and deliver it to an analytical
instrument for analysis without manual intervention.
The MAST® system (Modular Automated
Sampling Technology) is one such technology
that can reliably acquire samples from a process
stream and deliver them to multiple analytical
destinations for analysis. This is achieved
through the utilization of a sample pilot (Image
1) at each sample point to maintain an aseptic
cavity between the process stream and the
analyzers. The system completes a series of
steps to sanitize and dry the lines prior to
pushing a sample to its intended destination
with a diaphragm pump. This functionally closed
sampling nature and added sanitization
measures reduce contamination risks otherwise
present in manual sampling methods. In this
poster, we will show the benefits of having an
automated sampling system to reduce manual
labor, automate sample processing, and
expedite decision making with quicker access to
accurate process information.
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Figure 1. Layout of the MAST® automated sampling system used in the experiments

Combining Automated Sampling and Raman

Automated sampling can work together with other technologies such
as Raman spectroscopy to optimize the PAT toolbox. Using a
chemometric model calibrated in N-1 cultures, data was monitored inline using the ProCellics™ Raman analyzer with Bio4C® PAT Raman
Software to assess transferability to dynamic perfusion cultures. CPPs
were monitored on-line, using the MAST® system and shown in
comparison to the in-line Procellics™ Raman Analyzer data.

Results & Discussion

Figure 5. On-line VCD, Viability and Lactate and offline titer profiles obtained from the four
bioreactor runs.

The difference in the results obtained in dynamic run 2 was also
reflected in the glycan profiles (Figure 6). The alignment of these CPP
and CQA observations allows a correlation to be drawn between a
lactate shift and change in product quality. Gaining accelerated
access to both CPPs and CQAs through automated sampling and
sample processing allows for improved monitoring, facilitating quicker
and more informed decisions to adjust the process accordingly.

Sterility & Data Accuracy Assessment

Three perfusion bioreactor runs were completed successfully while
maintaining sterility with the analysis of four samples a day through
the MAST® system. This demonstrated proof of concept up to high
cell densities of over 150e6 cells/mL. When comparing nutrient &
metabolite data obtained with the MAST® system to data acquired
manually, data falls close to the y=x line indicating a strong
correlation between manual and automated data with an R2 value of
0.9965, slope of 0.9864 and intercept of 0.0655.
Figure 6. Glycan profiles obtained through LC-MS for the four perfusion runs.

Data obtained from the manual Protein A sample processing workflow
was comparable to data obtained with the automated Protein A
workflow using the MAST® system connected to the Gilson liquid
handler (Figure 7). This demonstrates the ability to simplify sample
processing through automation with the MAST® system. In the
future, we aim to automate the entire workflow to obtain on-line CQA
data without the need for operator intervention.

Image 1. The MAST®
Sample Pilot.

Material & Methods
Sterility & Data Accuracy Assessment

To assess the functionality of the MAST® system, three perfusion
bioreactor runs were executed in which automated samples were
scheduled 4X per day, every 6 hours. One run was operated in
N-1 perfusion mode while the other two runs were in steady
state perfusion mode where a cell bleed was implemented at
80e6 cells/mL. Daily manual samples were taken within 10
minutes of an automated sample and results from the Nova®
BioProfile® FLEX2 were compared between the two.

Precision and Ease in CPP Data Acquisition

Automated sampling was implemented in a perfusion process
development run to demonstrate the effects on data
acquisition. We compared a data set with daily manual samples
to a data set obtained through the MAST® system to evaluate the
impact on process performance and labor requirements while
obtaining critical process parameter data from the Nova
BioProfile® FLEX2 analyzer. We also looked at the robustness of
the technology to obtain sample data across a set of three
process development experiments that were run in parallel.

Figure 2. Cell growth profiles and alignment of manual and automated sample data for CPPs
across three bioreactor runs.

Precision and Ease in CPP Data Acquisition

Within the perfusion run, 4X more data was obtained with the MAST®
system while reducing the manual workload for sample acquisition by
over 8 hours. The increased frequency of sampling improved
granularity in data and consequently provided more information on
process performance. Increased frequency of data acquisition can
help to capture trends otherwise not captured with the regular daily
manual samples taken by an operator as seen in the irregular jumps
captured in the data from Day 17-20 (Figure 3). Across three process
development runs, there were 171 scheduled CPP samples and the
system successfully completed 97% sample delivery and analysis
(Figure 4).

Automated Workflow for CQA Data
Process Parameter
Process Mode

Run 1

Perfusion rate

Run 3

Run 4

Steady state perfusion

n/a

90e6 cells/mL

CSPR of 20 pL/cell/day up to 1
VVD

CSPR of 25 pL/cell/day (~2.2
VVD)

Vessel volume
CRD

Run 2

Dynamic perfusion

Cell bleed target

2.4 L

2.1 L

Cellicon® filter prototype
8 Micron PES membrane

Cellicon® filter prototype
3 Micron PES membrane

Bioreactor type
pH
DO

Automated sampling and Raman can be combined for improved
assessment of process performance. Automated sampling can be
used to acquire more frequent data during the modeling stage,
capturing the full range of each analyte, and leading to improved
accuracy or speed of model development. The alignment of the inline data to the on-line data helps validate the performance of the
sensor or catch any deviations that might have occurred with the
sensor (Figure 8).
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Figure 7. Comparison of select glycan profiles obtained using on-line and off-line Protein A sample
processing.
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Figure 8. On-line and In-line VCD, Glucose, Lactate and Ammonium profile
Figure 3. On-line and Offline Glucose, Viability, Ammonia and Lactate profiles.
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Table 1. Process parameters used in bioreactor runs to demonstrate accelerated access to
critical quality attributes.

Turnaround times for sample analysis of CQAs take an average of
2-6 weeks, becoming a limiting factor for the pace of process
development. In these experiments, we looked to reduce
workflow for LC-MS analysis by (1) implementing a new protocol
for peptide mapping that reduced the sample preparation workflow
from 2 days to 4 hours, and (2) connecting a 1 ml Eshmuno® A
column to the Gilson liquid handler as part of the MAST® system to
automatically purify the samples (Figure 1). Samples from four
different perfusion runs (Table 1) were analyzed on the Waters™
Bioaccord LC-MS system, and glycan profiles were compared from
run to run. Additionally, glycan profiles of manually completed
Protein A was compared to those completed automatically through
the MAST® system.

5 Missed Samples

171 samples
scheduled for a set
of 3 bioreactor runs

166 Successful
Samples

97% completed
successfully

Figure 4. Robustness of MAST® system to successfully deliver sample data.

Automated Workflow for CQA Data

CPP data from each of the four runs shows a difference in
performance between the dynamic and steady state process modes
(Figure 5). Dynamic runs reached higher peak VCD of ~120e6
cells/mL and dropped in viability sooner than the steady state runs,
which were maintained at 90e6 cells/ml with a high viability. The runs
showed variability in lactate profiles, especially when comparing
dynamic run 1, which experienced a lactate shift after day 10, with
dynamic run 2, which did not experience a lactate shift. This resulted
in a higher titer for dynamic run 2, as measured manually by HPLC.
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Summary
The MAST® automated sampling system allows for accelerated
access to CPP and CQA data through integration with analytical
instruments. The system is highly robust with its ability to acquire
and manage samples, ensuring both accurate and more frequent
data while maintaining a sterile barrier for the process stream.
Through its automation capabilities, it reduces the manual workload
needed in an upstream cell culture process. Additionally, it can be
combined with other PAT technologies such as Raman spectroscopy
for improved calibration and validation of data-driven models.

